Profile data is unavailable for this security.
About the company
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.
- Revenue in USD (TTM)0.00
- Net income in USD-436.82m
- Incorporated2013
- Employees254.00
- LocationVaxcyte Inc825 INDUSTRIAL ROAD, STE. 300SAN CARLOS 94070United StatesUSA
- Phone+1 (650) 837-0111
- Fax+1 (302) 655-5049
- Websitehttps://vaxcyte.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytokinetics, Inc. | 3.75m | -530.60m | 6.31bn | 423.00 | -- | -- | -- | 1,680.68 | -5.40 | -5.40 | 0.0382 | -3.78 | 0.0044 | -- | 4.08 | 8,869.98 | -62.50 | -43.14 | -69.19 | -47.22 | -- | -- | -14,141.74 | -540.47 | -- | -15.26 | 2.78 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
| Blueprint Medicines Corp | 282.21m | -288.29m | 6.49bn | 645.00 | -- | 20.88 | -- | 22.99 | -4.82 | -4.82 | 4.59 | 4.96 | 0.2499 | 0.3531 | 6.18 | 430,853.40 | -25.53 | -29.92 | -30.68 | -34.06 | 96.97 | -- | -102.15 | -116.65 | 3.61 | -23.37 | 0.4352 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
| Revolution Medicines Inc | 4.57m | -484.27m | 6.54bn | 411.00 | -- | 3.79 | -- | 1,433.06 | -3.76 | -3.76 | 0.035 | 10.46 | 0.0031 | -- | 2.29 | 12,079.37 | -32.48 | -29.76 | -34.18 | -32.59 | -- | -- | -10,606.04 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Jazz Pharmaceuticals PLC | 3.84bn | 330.79m | 6.74bn | 2.80k | 22.07 | 1.82 | 6.89 | 1.75 | 4.85 | 4.85 | 55.49 | 58.65 | 0.3436 | 0.6428 | 5.78 | 1,372,634.00 | 2.99 | 1.48 | 3.36 | 1.62 | 89.53 | 88.79 | 8.69 | 4.26 | 1.90 | 1.87 | 0.607 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
| Intra-Cellular Therapies Inc | 513.93m | -110.87m | 7.07bn | 610.00 | -- | 10.89 | -- | 13.76 | -1.15 | -1.15 | 5.34 | 6.15 | 0.6996 | 1.67 | 4.83 | 842,508.20 | -15.09 | -38.27 | -17.67 | -42.77 | 92.82 | -- | -21.57 | -128.42 | 5.00 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
| Viking Therapeutics Inc | 0.00 | -93.72m | 7.08bn | 28.00 | -- | 7.58 | -- | -- | -0.9305 | -0.9305 | 0.00 | 8.47 | 0.00 | -- | -- | 0.00 | -16.76 | -21.91 | -17.52 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
| Bellring Brands Inc | 1.84bn | 191.50m | 7.60bn | 420.00 | 40.52 | -- | 32.14 | 4.12 | 1.44 | 1.44 | 13.84 | -1.90 | 2.40 | 5.40 | 8.71 | 4,389,286.00 | 24.91 | 18.89 | 31.72 | -- | 32.74 | 32.44 | 10.39 | 10.10 | 1.84 | 5.07 | 1.42 | 0.00 | 21.53 | 15.03 | 101.09 | 13.80 | -18.48 | -- |
| Cerevel Therapeutics Holdings Inc | 0.00 | -460.47m | 7.61bn | 355.00 | -- | 13.46 | -- | -- | -2.72 | -2.72 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -44.76 | -- | -48.20 | -- | -- | -- | -- | -- | -- | -- | 0.3745 | -- | -- | -- | -23.14 | -- | -- | -- |
| Legend Biotech Corp (ADR) | 342.80m | -465.95m | 7.83bn | 1.80k | -- | 6.73 | -- | 22.84 | -2.60 | -2.60 | 1.90 | 6.39 | 0.2297 | 9.52 | 203.86 | 190,443.30 | -31.22 | -37.71 | -37.33 | -47.19 | 52.35 | -- | -135.92 | -286.51 | 5.57 | -24.44 | 0.2233 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
| Vaxcyte Inc | 0.00 | -436.82m | 8.01bn | 254.00 | -- | 4.04 | -- | -- | -4.22 | -4.22 | 0.00 | 18.24 | 0.00 | -- | -- | 0.00 | -28.19 | -34.22 | -29.52 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
| Elanco Animal Health Inc | 4.37bn | -1.30bn | 8.25bn | 9.30k | -- | 1.36 | -- | 1.89 | -2.64 | -2.64 | 8.84 | 12.26 | 0.2931 | 1.21 | 4.28 | 469,354.80 | -8.74 | -3.27 | -9.65 | -3.65 | 55.28 | 54.28 | -29.83 | -11.53 | 1.96 | 0.853 | 0.4877 | -- | 0.136 | 7.57 | -1,478.21 | -- | 2.74 | -- |
| KBR Inc | 7.07bn | -258.00m | 8.94bn | 34.00k | -- | 6.37 | -- | 1.26 | -1.91 | -1.91 | 52.67 | 10.46 | 1.25 | -- | 5.56 | 207,970.60 | -4.45 | 0.4725 | -6.46 | 0.6678 | 13.86 | 12.18 | -3.58 | 0.4122 | -- | 1.17 | 0.5678 | 340.00 | 5.97 | 7.20 | -240.21 | -- | 36.31 | 11.03 |
| Roivant Sciences Ltd | 123.24m | 4.35bn | 9.05bn | 904.00 | 2.22 | 1.48 | 2.12 | 73.43 | 5.07 | 5.23 | 0.1597 | 7.57 | 0.0259 | -- | 3.57 | 136,328.50 | 89.08 | -- | 105.17 | -- | 87.57 | -- | 3,439.02 | -- | 27.77 | -- | 0.0638 | -- | 10.84 | -- | -32.93 | -- | -- | -- |
| Repligen Corp | 607.45m | 14.84m | 9.33bn | 1.78k | 661.18 | 4.73 | 110.40 | 15.35 | 0.2524 | 0.2524 | 10.74 | 35.29 | 0.2255 | 1.43 | 4.87 | 340,689.80 | 0.551 | 4.38 | 0.6179 | 5.03 | 47.73 | 55.43 | 2.44 | 15.91 | 5.24 | -- | 0.2284 | 0.00 | -20.31 | 26.91 | -77.64 | 20.13 | 24.99 | -- |
Data as of May 21 2024. Currency figures normalised to Vaxcyte Inc's reporting currency: US Dollar USD
60.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 14.63m | 13.45% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 9.44m | 8.68% |
| RA Capital Management LPas of 31 Mar 2024 | 8.20m | 7.54% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 7.57m | 6.96% |
| Janus Henderson Investors US LLCas of 31 Mar 2024 | 7.41m | 6.81% |
| Wellington Management Co. LLPas of 31 Mar 2024 | 4.92m | 4.52% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2024 | 4.14m | 3.81% |
| T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 3.55m | 3.27% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.34m | 3.07% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 3.09m | 2.84% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
